Osimertinib for advanced EGFR-mutated lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older and able to sign informed consent.
- Your lung cancer should be advanced or spread, and not respond to surgery or radiation.
- Your tumor must have an EGFR “sensitizing” mutation (and you may also have a resistance mutation T790M), and you must not have had an EGFR-targeted pill before.
- Your general health should be fairly strong (ECOG score 0–1, and not worse in the last 2 weeks).
- Your blood counts and key organ tests (liver, kidney, bone marrow) must be within allowed ranges, checked within 28 days before starting.
- You must be able to take the study medicine by mouth and have at least one measurable cancer spot on a CT or MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
Hear when a new EGFR Positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.